Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 ...

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

At the FLORetina Conference in Florence, Italy, John W. Kitchens, of Retina Associates of Kentucky, highlighted strategies to enhance efficiency in retina practices, addressing challenges like staff ...

4D-150, based on the R100 vector, shows superior retinal cell transduction and efficacy in preclinical models compared to AAV2. The genetic medicine 4D-150 targets neovascular retinopathies by ...

eyeDNA Therapeutics announced it has been granted a Rare Pediatric Disease Designation (RPDD) by the FDA for HORA-PDE6b, its novel gene therapy for patients with inherited retinal dystrophy (IRD) ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and ...

AURN001, combining neltependocel and Y-27632, showed dose-dependent visual acuity improvement in corneal edema patients, with significant gains in the high-dose group. The CLARA trial demonstrated ...

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for. This series features experts in ophthalmology sharing their ...